Pipeline dossier

NIH & clinical-trial pipeline signals for ACADIA PHARMACEUTICALS INC (ACAD)

Leading indicators across the NIH grant → clinical trial → SEC filing chain for ACAD, mapped to public ticker ACAD (CIK 0001070494). Sourced live from public data.

⚠ Research/informational signals from public data (NIH · ClinicalTrials.gov · SEC EDGAR). Not investment advice. Full scope →

Trial → FilingACAD35% conf

ACADIA PHARMACEUTICALS INC (ACAD) — PHASE3 protocol updated 5 days ago

Upstream (observed)
Clinical trial status (PHASE3) — ACP-204 in Adults With Alzheimer's Disease Psychosis

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Recent SEC 8-K filings

2026-05-29 — 8-K 5.02,5.07,9.01 view ↗
2026-05-06 — 8-K 2.02,9.01 view ↗
2026-05-01 — 8-K 5.02,7.01,9.01 view ↗
2026-03-05 — 8-K 5.02 view ↗
2026-02-25 — 8-K 2.02,9.01 view ↗

JSON API for this entity →